Tuberculous drug-induced liver injury and treatment re-challenge in Human Immunodeficiency Virus co-infection

Tuberculous drug-induced liver injury and treatment re-challenge in Human Immunodeficiency Virus co-infection

Background: Tuberculosis drug-induced liver injury (TB-DILI) is the most common adverse event necessitating therapy interruption. The optimal re-challenge strategy for antituberculous therapy (ATT) remains unclear, especially in human immunodeficiency virus (HIV) co-infected individuals in high-prev...

Full description

Bibliographic Details
Main Authors: Cecilia T Costiniuk, Bernadett I Gosnell, Thandekile C Manzini, Camille N Du Plessis, Mahomed Yunus S Moosa
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Journal of Global Infectious Diseases
Subjects:
Anti-tuberculous treatment re-challenge
drug-induced liver injury
hepatotoxicity
human immunodeficiency virus
tuberculosis
Online Access:http://www.jgid.org/article.asp?issn=0974-777X;year=2015;volume=7;issue=4;spage=151;epage=156;aulast=Costiniuk

Internet

http://www.jgid.org/article.asp?issn=0974-777X;year=2015;volume=7;issue=4;spage=151;epage=156;aulast=Costiniuk

Similar Items